The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Lithium plus reserpine in refractory manic patients

Published Online:https://doi.org/10.1176/ajp.136.6.811

The authors report on six refractory manic or schizo-affective manic male outpatients who failed to respond to lithium combined with a neuroleptic. A beneficial response was noted in most patients when reserpine was substituted for their currently prescribed standard neuroleptic; in some cases lithium dosage could then be reduced. No major side effects were encountered. The use of reserpine may offer an alternative mode of therapy for manic patients who cannot tolerate large doses of lithium or do not completely respond to lithium either alone or in combination with a standard neuroleptic.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.